PURE

Pure Gold Mining Inc. Announces Non-Brokered Financing of C$3.45 Million

Retrieved on: 
Tuesday, October 5, 2021
NEWS, Indian stock exchange, Multilateral, Person, Sale, TSX Venture Exchange, MI, Pure, GLOBE, Puregold, Company, Mining, SARB, Pure Gold, Transaction, PURE, Security (finance), Cryptocurrency

VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Pure Gold Mining Inc. (TSXV:PGM LSE:PUR) (“PureGold” or the “Company”) is pleased to announce the Company has agreed to issue 3,307,619 units of the Company (the “Units”) at a price of C$1.05 per Unit (the “Transaction”) for gross proceeds of approximately C$3,473,000 on a non-brokered basis to Anglogold Ashanti Limited (“Anglogold”). Each Unit is comprised of one common share (each a “Common Share”) and one-half Common Share purchase warrant (each such full warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$1.36 for 18 months from the closing of the Transaction.

Key Points: 
  • Each Unit is comprised of one common share (each a Common Share) and one-half Common Share purchase warrant (each such full warrant, a Warrant).
  • ABOUT PURE GOLD MINING INC.
    PureGold is a growth company, located in the very heart of Red Lake, Canada.
  • To develop a highly-profitable long life gold mining company, becoming Canadas next iconic gold producer.
  • To expand organically, and develop PureGolds multi-million ounce high grade gold asset incrementally, step-by-step, using a phased mining development plan to deliver maximum return.

Clinical Data Acquired by the PURE EP™ System Published in the Journal of Cardiac Electrophysiology

Retrieved on: 
Monday, October 4, 2021
Online, Journal of Cardiovascular Electrophysiology, Northwestern University, University of Pennsylvania, PURE, NASDAQ, University of Colorado, FHRS, Nautilus, Inc. v. Biosig Instruments, Inc., Hospital, Decision-making, Principal, University, Electrophysiology, ST, Wiley (publisher), 3D, Journal, Mayo Clinic, Manuscript, Intracardiac injection, ECG, Massachusetts General Hospital, GLOBE, Medical imaging

The PURE EP 2.0 study was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. Davids Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital.

Key Points: 
  • The PURE EP 2.0 study was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. Davids Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital.
  • Intracardiac signal data of clinical interest were collected during 51 cardiac ablation procedures using the PURE EP System, the signal recording system, and the 3D mapping system at the same time stamps.
  • The results from the PURE EP 2.0 study clearly validate the clinical importance of our technology and position the Company for continued growth and success.
  • The Company's first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Pure Gold Mining Inc. Closes Bought Deal Offering for Gross Proceeds of C$23 Million

Retrieved on: 
Tuesday, September 28, 2021
NEWS, PI, Indian stock exchange, Exercise, Person, Sale, Unit, GLOBE, Offering, Puregold, Company, Prospectus, Mining, SEDAR, National instrument, PURE, Security (finance)

VANCOUVER, British Columbia, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Pure Gold Mining Inc. (TSXV:PGM LSE:PUR) (“PureGold” or the “Company”) is pleased to announce that it has closed its previously announced bought deal offering of 21,905,200 units of the Company (“Units”) at a price of C$1.05 per Unit for gross proceeds to the Company of C$23,000,460, which includes the full exercise of the underwriters’ over-allotment option for an additional 2,857,200 Units (the “Offering”). Each Unit is comprised of one common share (each a “Common Share”) and one-half Common Share purchase warrant (each such full warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$1.36 until March 28, 2023.

Key Points: 
  • Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$1.36 until March 28, 2023.
  • ABOUT PURE GOLD MINING INC.
    PureGold is a growth company, located in the very heart of Red Lake, Canada.
  • To develop a highly-profitable long life gold mining company, becoming Canadas next iconic gold producer.
  • To expand organically, and develop PureGolds multi-million ounce high grade gold asset incrementally, step-by-step, using a phased mining development plan to deliver maximum return.

BioSig Selects Plexus Corp. as its Manufacturing Partner

Retrieved on: 
Tuesday, September 28, 2021
EP, Partnership, Health, Risk, Security (finance), NASDAQ, U.S. Securities and Exchange Commission, FDA, Clinical professor, Plexus, Engineering, Patient, Physician, Nautilus, Inc. v. Biosig Instruments, Inc., Development, GLOBE, CEO, Cardiac electrophysiology, Company, COVID-19, Technology, Health care, New product development, Mayo Clinic, ECG, Nasdaq, Electrophysiology, SEC, PURE, Medical device, Pharmaceutical industry

Headquartered in Neenah, Wisconsin, Plexus Corp. counts healthcare and life sciences as one of its largest market sectors representing nearly 40% of annual revenue.

Key Points: 
  • Headquartered in Neenah, Wisconsin, Plexus Corp. counts healthcare and life sciences as one of its largest market sectors representing nearly 40% of annual revenue.
  • Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSigs growth objectives now and well into the future.
  • Plexus has a team of over 19,000 individuals who are dedicated to providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Aftermarket Services.
  • Plexus is a global leader that specializes in serving customers in industries with highly complex products and demanding regulatory environments.

BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors

Retrieved on: 
Tuesday, September 21, 2021
System, Convergent, Corporate Technology Directory, EP, Risk, Security (finance), Board of directors, Doctor of Philosophy, FDA, Clinical professor, U.S. Securities and Exchange Commission, Saint Anselm College, Patient, Arsenal, BSX, Physician, University of Massachusetts Lowell, Nautilus, Inc. v. Biosig Instruments, Inc., Board, CEO, Industry, Cardiac electrophysiology, Company, University, SR, COVID-19, Boston Scientific, Mayo Clinic, Learning, ECG, Nasdaq, NYSE, Electrophysiology, SEC, PURE, NSPR, GLOBE, Pharmaceutical industry, Management

Dr. Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director.

Key Points: 
  • Dr. Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director.
  • He is currently the Principal Owner at Convergent Biomedical Group LLC., a company providing advisory services to the life sciences industry.
  • Prior to Convergent, Dr. Barry was President and CEO at InspireMD, Inc. (Nasdaq: NSPR) and platform technology company, Arsenal Medical.
  • Jims accomplishments in the medical device sector are second-to-none, and we are thrilled that he can join us as our new Independent Director.

Prodeon Medical Announces Presentation of Interim Results from its EXPANDER-1 Multicenter Clinical Trial for its Urocross™ Expander System for Symptoms related to Benign Prostatic Hyperplasia

Retrieved on: 
Thursday, September 16, 2021
Prostate, Taipei Veterans General Hospital, National university, Cystoscopy, Lower urinary tract symptoms, Sequela, General Hospital, Man, University, Technology, Trial of the century, Department of Urology, University of Virginia, Patient, LUTS, Anatomy, PURE, Safety, American Urological Association, Prostatic urethral lift, Department, Taipei Medical University Hospital, International Prostate Symptom Score, BPH, AUA, Sale, IPSS, Medical imaging

Prof Woo stated, "Based on these early results, we are thrilled that the primary clinical objective of the feasibility and safety study have been positive."

Key Points: 
  • Prof Woo stated, "Based on these early results, we are thrilled that the primary clinical objective of the feasibility and safety study have been positive."
  • Preliminary results from 39 patients treated in this study demonstrate that the procedure using the Urocross Expander System is feasible and safe with no reported procedural complications.
  • The Urocross Expander System consists of two primary components: the Urocross Delivery System and the preloaded Urocross Expander Implant.
  • The Prodeon Medical initiative was started in 2016 with the mission of rethinking the treatment of the lower urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH).

Tineco Unveils New Flagship Floor Washer Series

Retrieved on: 
Wednesday, September 15, 2021
Water, Vacuum, Efficiency, Technology, Best Buy, Walmart, CAN, MSRP, PRO, PURE, Combo, LCD, Fresh water, Suction, Consumer electronics, Milk, Cryptocurrency

SEATTLE, Sept. 15, 2021 /PRNewswire/ --Tineco, a leading innovator in floor care and small appliances, unveils a new flagship series to the smart wet/dry vacuum category, FLOOR ONE S5.

Key Points: 
  • SEATTLE, Sept. 15, 2021 /PRNewswire/ --Tineco, a leading innovator in floor care and small appliances, unveils a new flagship series to the smart wet/dry vacuum category, FLOOR ONE S5.
  • The expanded Tineco FLOOR ONE line-up builds on the market leading performance of FLOOR ONE S3 winner of the 2021 Good Housekeeping Cleaning Awards.
  • The FLOOR ONE S5 series includes the FLOOR ONE S5, FLOOR ONE S5 PRO, and FLOOR ONE S5 COMBO, and features include:
    Enhanced Edge Cleaning: The exclusive FLOOR ONE S5 brush head is designed to clean hard to reach corners and along baseboards.
  • The Tineco iFloor 2 cordless floor washer features a larger brush head and an updated design that achieves four times better cleaning efficiency than the original iFloor.

Proactive news headlined including Apple, Gevo, Esports Entertainment, BioSig and Ascendant Resources

Retrieved on: 
Monday, September 13, 2021
Nautilus, Inc. v. Biosig Instruments, Inc., PURE, ST, GLOBE, Ascendant, Research, SEO, News, Proactivity, Gold, Video game, Public relations

Proactives network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

Key Points: 
  • Proactives network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.
  • Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
  • We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

BioSig Increases Installation Footprint Adding St. Elizabeth’s Medical Center to Roster of Premium Medical Institutions Utilizing the PURE EP System

Retrieved on: 
Monday, September 13, 2021
Risk, CDC, Health, U.S. Securities and Exchange Commission, Security (finance), Heart, Nautilus, Inc. v. Biosig Instruments, Inc., Arrhythmia, CEO, FDA, Boston University, Clinical professor, Atrial fibrillation, Mayo Clinic, Patient, Company, Electrophysiology, Nasdaq, PURE, Medical Center, Hospital, Physician, Cardiac electrophysiology, COVID-19, ECG, Center, GLOBE, EP, Korea Disease Control and Prevention Agency, Scripps Health, SEC, Goal, Elective surgery, Woman, Acquisition, Leadership, St. Elizabeth's, Medical imaging, Medical device, Pharmaceutical industry

Physiologic pacing is an emerging pacing technique designed to activate the normal cardiac conduction system and synchronize contraction of the ventricles.

Key Points: 
  • Physiologic pacing is an emerging pacing technique designed to activate the normal cardiac conduction system and synchronize contraction of the ventricles.
  • This approach to pacing the heart has demonstrated improved clinical and hemodynamic benefits beyond standard pacing techniques.
  • We are pleased to grow our clinical presence in Boston and collaborate with Dr. Orlov on this expanded use of the PURE EP(tm) System.
  • The physiologic pacing procedure could benefit from advanced signal information to optimize lead placement and improve procedural outcomes.

BioSig Confirmed as a Participant of The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Virtual Symposium

Retrieved on: 
Tuesday, August 31, 2021
Industry, Company, Center, University, Atrial fibrillation, Observation, Program, Scripps Health, ECG, U.S. Securities and Exchange Commission, Arrhythmia, Diagnosis, GLOBE, SEC, Harvard Medical School, Cardiac electrophysiology, Science, CDC, Physician, Security (finance), PURE, Nasdaq, Cardiology, Risk, Leonard, Electrophysiology, Korea Disease Control and Prevention Agency, Patient, Sudden death, Textbook, Faculty, CEO, Nautilus, Inc. v. Biosig Instruments, Inc., FDA, COVID-19, Technology, Health, Medical device

He was the Herman Dana Professor of Medicine at Harvard Medical School and the director of the Harvard-Thorndike Electrophysiology Institute and Arrhythmia Service.

Key Points: 
  • He was the Herman Dana Professor of Medicine at Harvard Medical School and the director of the Harvard-Thorndike Electrophysiology Institute and Arrhythmia Service.
  • These courses were attended by almost all electrophysiology trainees in the U.S. for over ten years.
  • This symposium pays tribute to the scientific and clinical legacy of Dr. Mark E. Josephson who served as a mentor to many of the faculty.
  • Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov.